Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiba, N.
Right arrow Articles by Parvin, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiba, N.
Right arrow Articles by Parvin, J. D.
[Cancer Research 62, 4222-4228, August 1, 2002]
© 2002 American Association for Cancer Research


Biochemistry and Biophysics

The BRCA1 and BARD1 Association with the RNA Polymerase II Holoenzyme1

Natsuko Chiba and Jeffrey D. Parvin2

Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

We have previously shown that endogenous BRCA1 and overexpressed epitope-tagged BRCA1are present in the transcription complex called the RNA polymerase II holoenzyme (holo-pol). In this study, we further characterized BRCA1 association with the holo-pol by overexpressing deletion mutants of epitope-tagged BRCA1. We found that BRCA1-associated RING domain protein (BARD1) is a component of the holo-pol complex. Deletion of the BRCA1 NH2 terminus, which is bound by BARD1 as well as other proteins, eliminates >98% of BRCA1 association with the holo-pol. In contrast with earlier observations, deletion of the COOH terminus of BRCA1 did not affect significantly the association with holo-pol. Immunocytochemistry of expressed full-length and deletion mutants of BRCA1 showed that the NH2 terminus of BRCA1 is important for nuclear dot formation in S-phase. An intact BRCA1 NH2 terminus is required for the association with holo-pol and for subnuclear localization in S-phase foci. Taken together, these data support a role for BRCA1 regulation of holo-pol function.




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
Y. Lin and J. H. Wilson
Transcription-Induced CAG Repeat Contraction in Human Cells Is Mediated in Part by Transcription-Coupled Nucleotide Excision Repair
Mol. Cell. Biol., September 1, 2007; 27(17): 6209 - 6217.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
N. E. Buckley, A. M. Hosey, J. J. Gorski, J. W. Purcell, J. M. Mulligan, D. P. Harkin, and P. B. Mullan
BRCA1 Regulates IFN-{gamma} Signaling through a Mechanism Involving the Type I IFNs
Mol. Cancer Res., March 1, 2007; 5(3): 261 - 270.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. Wu, H. Nishikawa, R. Hayami, K. Sato, A. Honda, S. Aratani, T. Nakajima, M. Fukuda, and T. Ohta
BRCA1 Ubiquitinates RPB8 in Response to DNA Damage
Cancer Res., February 1, 2007; 67(3): 951 - 958.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. P. Schlegel, F. M. Jodelka, and R. Nunez
BRCA1 Promotes Induction of ssDNA by Ionizing Radiation.
Cancer Res., May 15, 2006; 66(10): 5181 - 5189.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. A. Horwitz, S. Sankaran, and J. D. Parvin
Direct Stimulation of Transcription Initiation by BRCA1 Requires Both Its Amino and Carboxyl Termini
J. Biol. Chem., March 31, 2006; 281(13): 8317 - 8320.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. M. Simons, A. A. Horwitz, L. M. Starita, K. Griffin, R. S. Williams, J.N. M. Glover, and J. D. Parvin
BRCA1 DNA-Binding Activity Is Stimulated by BARD1
Cancer Res., February 15, 2006; 66(4): 2012 - 2018.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. M. Starita, A. A. Horwitz, M.-C. Keogh, C. Ishioka, J. D. Parvin, and N. Chiba
BRCA1/BARD1 Ubiquitinate Phosphorylated RNA Polymerase II
J. Biol. Chem., July 1, 2005; 280(26): 24498 - 24505.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. D. Choudhury, H. Xu, A. P. Modi, W. Zhang, T. Ludwig, and R. Baer
Hyperphosphorylation of the BARD1 Tumor Suppressor in Mitotic Cells
J. Biol. Chem., July 1, 2005; 280(26): 24669 - 24679.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
F. E. Kleiman, F. Wu-Baer, D. Fonseca, S. Kaneko, R. Baer, and J. L. Manley
BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II
Genes & Dev., May 15, 2005; 19(10): 1227 - 1237.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Wu-Baer, K. Lagrazon, W. Yuan, and R. Baer
The BRCA1/BARD1 Heterodimer Assembles Polyubiquitin Chains through an Unconventional Linkage Involving Lysine Residue K6 of Ubiquitin
J. Biol. Chem., September 12, 2003; 278(37): 34743 - 34746.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Benezra, N. Chevallier, D. J. Morrison, T. K. MacLachlan, W. S. El-Deiry, and J. D. Licht
BRCA1 Augments Transcription by the NF-{kappa}B Transcription Factor by Binding to the Rel Domain of the p65/RelA Subunit
J. Biol. Chem., July 11, 2003; 278(29): 26333 - 26341.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.